Illumina, Inc.
Illumina Reports Q2 2025 Financial Results and Provides Updated Fiscal Year Guidance
Summary
Illumina, Inc. announced financial results for the second quarter of fiscal year 2025, reporting revenue of $1.06 billion, a 3% decline from Q2 2024. The company delivered a GAAP operating margin of 20.2% and a non-GAAP operating margin of 23.8%. GAAP diluted earnings per share (EPS) were $1.49, compared to $0.41 in the same period last year, while non-GAAP diluted EPS were $1.19. The company also provided updated fiscal year guidance, anticipating total company constant currency revenue decline in the range of (2.5%) to (0.5%), non-GAAP operating margin of approximately 22% - 22.5%, and non-GAAP diluted EPS in the range of $4.45 - $4.55. Additionally, Illumina entered into a definitive agreement to acquire SomaLogic from Standard BioTools, expected to close in the first half of 2026.
Profitelligence Alerts
Get alerts for ILMN
Be first to know when Illumina, Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Illumina, Inc.
Illumina, Inc. operates as a global leader in the life sciences industry, focusing on the development and manufacturing of integrated systems for the analysis of genetic variation and function. Primarily, Illumina’s products and services are pivotal in advancing genomic research, enabling scientists to explore DNA sequencing and genetic mapping with high precision and efficiency. The company’s solutions are extensively utilized in fields such as oncology, reproductive health, and genetic disease diagnostics. Known for its cutting-edge sequencing tools, Illumina plays a crucial role in driving innovation in personalized medicine, helping to tailor medical treatments to individual genetic profiles. Headquartered in San Diego, California, Illumina contributes significantly to the genomics sector’s expansion, supporting initiatives in health and medicine, agrigenomics, and microbiology. By providing critical tools for genetic analysis, Illumina aids researchers and clinical laboratories worldwide, influencing how healthcare is approached and offering insights into complex biological systems.
Official SEC Documents
Advertisement